What is the epidemiology and burden of diabetic foot ulcers globally and in India?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Epidemiology and Burden of Diabetic Foot Ulcers

Global Epidemiology

Diabetic foot ulcers affect approximately 18.6 million people worldwide annually, with a global incidence of 10.93 cases per 1,000 person-years and a prevalence of 54.57 active ulcers per 1,000 persons with diabetes 1, 2.

Key Global Statistics

  • Incidence rates 1:

    • Active ulcerations: 10.93 per 1,000 person-years
    • Amputations: 3.58 per 1,000 person-years
    • Infections: 19.11 per 1,000 person-years

  • Prevalence estimates 1:

    • Active ulcers: 54.57 per 1,000 persons (5.5%)
    • Past ulcers: 72.63 per 1,000 persons (7.3%)
    • Amputations: 14.75 per 1,000 persons
    • Infections: 39.17 per 1,000 persons

The most recent 2026 meta-analysis 1 provides more granular data than the older 2017 estimate of 6.3% global prevalence 3, reflecting improved methodology and data sources.

Geographic Variation

America and Africa have rates above the global average, while Europe, Asia, and Oceania fall below 1. Specifically:

  • North America: 13.0% prevalence (highest globally) 3
  • Africa: 7.2% prevalence 3
  • Asia: 5.5% prevalence 3
  • Europe: 5.1% prevalence 3
  • Oceania: 3.0% prevalence (lowest) 3

Demographic Patterns

  • Males have higher prevalence (4.5%) than females (3.5%) 3
  • Type 2 diabetes patients show higher rates (6.4%) compared to Type 1 (5.5%) 3
  • Elderly patients (≥60 years) have 2.86 times higher odds of developing DFU 4

India-Specific Burden

The incidence of diabetic foot ulcers in urban India is 66 cases per 10,000 people with diabetes per year (0.66%) 4, which appears lower than global estimates but likely reflects underreporting and limited community-level surveillance.

Critical India Data Points

  • Amputation rates in India are alarmingly high: 43.4% of DFU patients required amputation in one tertiary care study 5, substantially exceeding conventional global estimates
  • 15.29% of DFU patients required amputation in a community healthcare setting 4
  • Recurrence is extremely common: 42.4% of patients experience ulcer recurrence, with 66.1% occurring on the same side 5
  • Previous amputation triples the risk of subsequent amputation (OR 3.08) 5

Time Course in India

  • Median healing time: 3 months 5
  • Time to recurrence: 4.23 years among those with amputation versus 9.61 years in those who healed 5
  • Recurrence rates: 42% at 1 year and 65% at 5 years globally 2

Risk Factors in Indian Population

Poor glycemic control (HbA1c >7%) increases DFU odds by 1.71 times 4. Additional risk factors include:

  • Longer diabetes duration (median 15 years in DFU patients) 5
  • Elderly age (OR 2.863 for ≥60 years) 4
  • Previous ulcer history (OR 2.41) 1
  • Coronary artery disease (OR 2.08) 6

Mortality and Morbidity Burden

The 5-year mortality rate for individuals with diabetic foot ulcers is approximately 30%, exceeding 70% for those with major amputation 2. This represents a mortality rate of 231 deaths per 1,000 person-years compared to 182 per 1,000 in diabetics without foot ulcers 2.

Long-term Mortality in India

At median follow-up of 6.08 years 5:

  • 1-year mortality: 2.5% (amputation) vs 0% (healing)
  • 3-year mortality: 2.5% (amputation) vs 0% (healing)
  • 5-year mortality: 8.2% (amputation) vs 10.1% (healing)
  • 10-year mortality: 30.9% (amputation) vs 24.5% (healing)

Cardiovascular death is the leading cause of mortality, followed by sepsis 5.

Infection and Amputation Burden

Approximately 50-60% of diabetic foot ulcers become infected, and about 20% of moderate to severe infections lead to lower extremity amputations 2. These ulcers precede 80% of all lower extremity amputations in people with diabetes 2.

Healthcare System Gaps in India

A critical 2026 survey revealed severe fragmentation in diabetic foot care 7:

  • Only 16% of institutions have written protocols despite 94% favoring dedicated clinics
  • Care remains scattered across plastic surgery (50%), general surgery (25%), orthopedics (16%), and vascular surgery (9%)
  • Lack of coordinated multidisciplinary pathways contributes to poor outcomes

Clinical Implications

The burden is substantially underestimated due to limited follow-up and fragmented care systems, particularly in India 5. The disparity between India's reported community incidence (0.66%) and tertiary care amputation rates (43.4%) suggests massive gaps in early detection and prevention.

Health Disparities

Black, Hispanic, and Native American populations, along with those of low socioeconomic status, have higher rates of DFU and subsequent amputation compared to White populations 2, highlighting the need for targeted interventions in vulnerable communities.

References

1
Research

Global Epidemiology of Diabetic Foot: A Systematic Review and Meta-Analysis.

Diabetes/metabolism research and reviews, 2026

7
Research

A Survey: Who Manages the Diabetic Foot in India?

Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India, 2026

Related Questions

How should recurrent diabetic foot ulcers be treated and prevented?
What is the appropriate surgical treatment approach for a diabetic patient with a foot ulcer?
In a 65-year-old diabetic patient with a non-healing 5 × 5 cm ulcer on the anterolateral distal tibia above the ankle, multiple twisted superficial veins, a normal dorsalis pedis pulse, intermittent fever for two days, and leukocytosis, what is the diagnosis and appropriate treatment to heal the ulcer?
What are the epidemiology, risk factors, and healthcare burden associated with diabetic foot ulcers?
In a 35-year-old female with end-stage renal disease on thrice-weekly hemodialysis, type 2 diabetes mellitus, severe peripheral vascular disease, legal blindness, bilateral toe amputations, and a non-healing left foot ulcer with constant 10/10 burning pain (currently on ciprofloxacin after dialysis and requesting home-health skilled nursing), who now presents with acute right calf pain that worsens with standing and ambulation, is tender to touch, and raises concern for deep‑vein thrombosis, what is the appropriate urgent evaluation and management plan?
What is the appropriate management of heavy menstrual bleeding following Implanon (etonogestrel implant) insertion?
What are the epidemiology, risk factors, and healthcare burden associated with diabetic foot ulcers?
Should fulvestrant be given before or after an aromatase inhibitor in the treatment sequence for hormone receptor‑positive breast cancer?
In a post‑menopausal woman with hormone‑receptor‑positive, HER2‑positive metastatic breast cancer, should trastuzumab emtansine (T‑DM1) be given before or after fulvestrant?
How should a reproductive‑age woman with a shortened menstrual interval (cycles <21 days) be evaluated and managed?
What are the latest treatment options for human papillomavirus (HPV) infection and associated lesions?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.